The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Diversity of molecular targets and signaling pathways for CBD
Open accessAbstract
Cannabidiol (CBD) is the second most abundant component of the Cannabis plant and is known to have effects distinct from Δ 9‐tetrahydrocannabinol (THC). Many studies that examined the behavioral effects of CBD concluded that it lacks the psychotomimetic effects attributed to THC. However, CBD was shown to have a broad spectrum of effects on several conditions such as anxiety, inflammation, neuropathic pain, and epilepsy. It is currently thought that CBD engages different targets and hence CBD’s effects are thought to be due to multiple molecular mechanisms of action. A well‐accepted set of targets include GPCRs and ion channels, with the serotonin 5‐HT 1A receptor and the transient receptor potential cation channel TRPV1 channel being the two main targets. CBD has also been thought to target G protein‐coupled receptors (GPCRs) such as cannabinoid and opioid receptors. Other studies have suggested a role for additional GPCRs and ion channels as targets of CBD. Currently, the clinical efficacy of CBD is not completely understood. Evidence derived from randomized clinical trials, in vitro and in vivo models and real‐world observations support the use of CBD as a drug treatment option for anxiety, neuropathy, and many other conditions. Hence an understanding of the current status of the field as it relates to the targets for CBD is of great interest so, in this review, we include findings from recent studies that highlight these main targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,646
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Endocannabinoid Signaling and Synaptic Function
Castillo, P. E., Younts, T. J., Chávez, A. E., & Hashimotodani, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.020 · Cited by 1,120
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
Sucrose preference test for measurement of stress-induced anhedonia in mice
Liu, M.-Y., Yin, C.-Y., Zhu, L.-J., Zhu, X.-H., Xu, C., Luo, C.-X., Chen, H., Zhu, D.-Y., & Zhou, Q.-G. (2018) · Nature Protocols · doi:10.1038/s41596-018-0011-z · Cited by 1,026
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors
Alexander, S. P., Davenport, A. P., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13348 · Cited by 851
Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T., & Yirmiya, R. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002055 · Cited by 762
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 756
Janani, C., & Ranjitha Kumari, B. D. (2015) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2014.09.015 · Cited by 735
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14748 · Cited by 702
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 695
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., La Torre, F., Fabiani, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01526 · Cited by 616
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels
Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14749 · Cited by 606
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications
de Lera Ruiz, M., & Kraus, R. L. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501981g · Cited by 548
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
O'Sullivan, S. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707423 · Cited by 510
Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497
Mechoulam, R. (1970) · Science · doi:10.1126/science.168.3936.1159 · Cited by 492
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
Cannabidiol in Anxiety and Sleep: A Large Case Series
Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019) · The Permanente Journal · doi:10.7812/tpp/18-041 · Cited by 432
Iannotti, F. A., Hill, C. L., Leo, A., Alhusaini, A., Soubrane, C., Mazzarella, E., Russo, E., Whalley, B. J., Di Marzo, V., & Stephens, G. J. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5000524 · Cited by 413
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors
Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-006-0033-x · Cited by 377
Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364
Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats
Cheer, J. F., Wassum, K. M., Heien, M. L. A. V., Phillips, P. E. M., & Wightman, R. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-04.2004 · Cited by 343
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., & Rogers, M. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902743106 · Cited by 330
Rios, C., Gomes, I., & Devi, L. A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706757 · Cited by 327
Self-citationEffects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307
The enigmatic pharmacology of GPR55
Ross, R. A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.004 · Cited by 296
Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., & Díaz, Á. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.017 · Cited by 279
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G., Jiang, Q., Mandrekar, S., & Heneka, M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277
Ward, S. J., McAllister, S. D., Kawamura, R., Murase, R., Neelakantan, H., & Walker, E. A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12439 · Cited by 276
Philpott, H. T., O'Brien, M., & McDougall, J. J. (2017) · Pain · doi:10.1097/j.pain.0000000000001052 · Cited by 268
G protein-coupled receptor heteromers
Gomes, I., Ayoub, M. A., Fujita, W., Jaeger, W. C., Pfleger, K. D. G., & Devi, L. A. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135952 · Cited by 262
Self-citationJadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., O’Sullivan, S. E., & Tan, G. D. (2016) · Diabetes Care · doi:10.2337/dc16-0650 · Cited by 262
Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+Levels
Ryan, D., Drysdale, A. J., Lafourcade, C., Pertwee, R. G., & Platt, B. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4212-08.2009 · Cited by 255
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-0015 · Cited by 241
Freeman, A. M., Petrilli, K., Lees, R., Hindocha, C., Mokrysz, C., Curran, H. V., Saunders, R., & Freeman, T. P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.036 · Cited by 222
Inhibitory effects of cannabidiol on voltage-dependent sodium currents
Ghovanloo, M.-R., Shuart, N. G., Mezeyova, J., Dean, R. A., Ruben, P. C., & Goodchild, S. J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004929 · Cited by 204
Neuroprotective Antioxidants from Marijuanaa
HAMPSON, A. J., GRIMALDI, M., LOLIC, M., WINK, D., ROSENTHAL, R., & AXELROD, J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06193.x · Cited by 203
Bubier, J. A., Wilcox, T. D., Jay, J. J., Langston, M. A., Baker, E. J., & Chesler, E. J. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00001 · Cited by 198
Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, M. L., Vitoretti, L. B., Mariano-Souza, D. P., Quinteiro-Filho, W. M., Akamine, A. T., Almeida, V. I., Quevedo, J., Dal-Pizzol, F., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.043 · Cited by 185
Seeman, P. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.195 · Cited by 176
Maione, S., Piscitelli, F., Gatta, L., Vita, D., De Petrocellis, L., Palazzo, E., de Novellis, V., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01063.x · Cited by 175
Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors
MacLennan, S. J., Reynen, P. H., Kwan, J., & Bonhaus, D. W. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701915 · Cited by 175
Hurd, Y. L., Yoon, M., Manini, A. F., Hernandez, S., Olmedo, R., Ostman, M., & Jutras-Aswad, D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0373-7 · Cited by 167
Petrosino, S., Verde, R., Vaia, M., Allarà, M., Iuvone, T., & Marzo, V. D. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244368 · Cited by 166
Understanding the Molecular Aspects of Tetrahydrocannabinol and Cannabidiol as Antioxidants
Borges, R. S., Batista, J., Viana, R. B., Gonçalves, A. C. B., Orestes, E., de Andrade, M. A., Honório, K. M., & da Silva, A. B. F. (2013) · Molecules · doi:10.3390/molecules181012663 · Cited by 162
Cannabis for the Treatment of Epilepsy: an Update
Gaston, T. E., & Szaflarski, J. P. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0882-y · Cited by 162
Cannabidiol reduces ethanol consumption, motivation and relapse in mice
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Navarrón, C. M., Morales‐Calero, M. I., Navarrete, F., Torres‐Suárez, A. I., & Manzanares, J. (2017) · Addiction Biology · doi:10.1111/adb.12495 · Cited by 161
Pertwee, R. G., Ross, R. A., Craib, S. J., & Thomas, A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02624-9 · Cited by 156
Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray
Moreira, F. A., de Aguiar, D. C., & Guimarães, F. S. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.013 · Cited by 153
Differential Regulation of Adipocytokine mRNAs by Rosiglitazone in db/db Mice
Moore, G. B. T., Chapman, H., Holder, J. C., Lister, C. A., Piercy, V., Smith, S. A., & Clapham, J. C. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5460 · Cited by 151
Hojo, M., Sudo, Y., Ando, Y., Minami, K., Takada, M., Matsubara, T., Kanaide, M., Taniyama, K., Sumikawa, K., & Uezono, Y. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08244fp · Cited by 148
Massi, P., Valenti, M., Vaccani, A., Gasperi, V., Perletti, G., Marras, E., Fezza, F., Maccarrone, M., & Parolaro, D. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05073.x · Cited by 141
Katsidoni, V., Anagnostou, I., & Panagis, G. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00483.x · Cited by 136
Vilela, L., Lima, I. V. D. A., Kunsch, É. B., Pinto, H. P. P., de Miranda, A. S., Vieira, É. L. M., de Oliveira, A. C. P., Moraes, M. F. D., Teixeira, A. L., & Moreira, F. A. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.07.014 · Cited by 134
Ward, S. J., Ramirez, M. D., Neelakantan, H., & Walker, E. A. (2011) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3182283486 · Cited by 133
Galaj, E., Bi, G., Yang, H.-J., & Xi, Z. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107740 · Cited by 118
Jesus, C. H. A., Redivo, D. D. B., Gasparin, A. T., Sotomaior, B. B., de Carvalho, M. C., Genaro, K., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., Zanoveli, J. M., et al. (2019) · Brain Research · doi:10.1016/j.brainres.2019.03.014 · Cited by 113
GPR55: A therapeutic target for Parkinson's disease?
Celorrio, M., Rojo-Bustamante, E., Fernández‐Suárez, D., Sáez, E., de Mendoza, A. E., Müller, C. E., Ramírez, M. J., Oyarzábal, J., Franco, R., & Aymerich, M. S. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.017 · Cited by 111
Prohedonic effect of cannabidiol in a rat model of depression
Shoval, G., Shbiro, L., Hershkovitz, L., Hazut, N., Zalsman, G., Mechoulam, R., & Weller, A. (2016) · Neuropsychobiology · doi:10.1159/000443890 · Cited by 110
The Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias
Gonca, E., & Darıcı, F. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414532013 · Cited by 106
Hippocampal telomerase is involved in the modulation of depressive behaviors
Zhou, Q.-G., Hu, Y., Wu, D.-L., Zhu, L.-J., Chen, C., Jin, X., Luo, C.-X., Wu, H.-Y., Zhang, J., & Zhu, D.-Y. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0805-11.2011 · Cited by 105
Modulation of rat brain opioid receptors by cannabinoids.
VAYSSE, P. J. ‐., Gardner, E. L., & Zukin, R. S. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00276-9 · Cited by 103
Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon
Couch, D. G., Tasker, C., Theophilidou, E., Lund, J. N., & O’Sullivan, S. E. (2017) · Clinical Science · doi:10.1042/cs20171288 · Cited by 98
Hudson, R., Renard, J., Norris, C., Rushlow, W. J., & Laviolette, S. R. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0708-19.2019 · Cited by 97
Prenatal cocaine and/or nicotine exposure produces depression and anxiety in aging rats
Sobrian, S. K., Marr, L., & Ressman, K. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00042-3 · Cited by 92
Alexander, S., Mathie, A. A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_3.x · Cited by 90
Espejo‐Porras, F., Fernández‐Ruíz, J., Pertwee, R. G., Mechoulam, R., & García, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.024 · Cited by 79
Hacke, A. C. M., Lima, D., de Costa, F., Deshmukh, K., Li, N., Chow, A. M., Marques, J. A., Pereira, R. P., & Kerman, K. (2019) · The Analyst · doi:10.1039/c9an00890j · Cited by 77
Manduca, A., Lassalle, O., Sepers, M., Campolongo, P., Cuomo, V., Marsicano, G., Kieffer, B., Vanderschuren, L. J. M. J., Trezza, V., & Manzoni, O. J. J. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00211 · Cited by 73
In Vitro and In Vivo Efficacy of Non-Psychoactive Cannabidiol in Neuroblastoma
Fisher, T., Golan, H., Schiby, G., Pri‐Chen, S., Smoum, R., Moshe, I., Peshes‐Yaloz, N., Castiel, A., Waldman, D., Gallily, R., et al. (2016) · Current Oncology · doi:10.3747/co.23.2893 · Cited by 72
Cannabidiol: Swinging the Marijuana Pendulum From ‘Weed’ to Medication to Treat the Opioid Epidemic
Hurd, Y. L. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2016.12.006 · Cited by 72
Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes
Lehmann, C., Fisher, N. B., Tugwell, B. D., Szczesniak, A. M., Kelly, M. E. M., & Zhou, J. (2016) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-168021 · Cited by 70
Štark, T., Bartolomeo, M. D., Marco, R. D., Dražanová, E., Platania, C. B. M., Iannotti, F. A., Kučerová, J., D’Addario, C., Krátká, L., Pekařík, V., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114004 · Cited by 64
The Role of Thiazolidinediones in the Treatment of Patients with Type 2 Diabetes Mellitus
Mooradian, A. D., Chehade, J. M., & Thurman, J. E. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201010-00002 · Cited by 48
A cannabinoid with cardiovascular activity but no overt behavioral effects
Adams, M. D., Earnhardt, J. T., Martin, B. R., Harris, L. S., Dewey, W. L., & Razdan, R. K. (1977) · Cellular and Molecular Life Sciences · doi:10.1007/bf01922330 · Cited by 48
Sierra, S., Gupta, A., Gomes, I., Fowkes, M. E., Ram, A., Bobeck, E. N., & Devi, L. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00008 · Cited by 48
Self-citationEffects of cannabidiol on contractions and calcium signaling in rat ventricular myocytes
Ali, R. M., Kury, L. T. A., Yang, K. S., Qureshi, A., Rajesh, M., Galadari, S., Шуба, Я. М., Howarth, F. C., & Öz, M. (2015) · Cell Calcium · doi:10.1016/j.ceca.2015.02.001 · Cited by 44
Juknat, A., Kozela, E., Kaushansky, N., Mechoulam, R., & Vogel, Z. (2015) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2015-0071 · Cited by 44
Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo
Ugur, M., Derouiche, L., & Massotte, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01240 · Cited by 43
Hudson, R., Rushlow, W. J., & Laviolette, S. R. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4766-7 · Cited by 41
Cited by
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Pharmacologic treatments for gastroparesis
Camilleri, M., & Jencks, K. J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100019 · Cited by 14
Metadata
- Authors
- de Almeida, D. L., & Devi, L. A.
- Venue
- Pharmacology Research & Perspectives
- Publisher
- Wiley
- Published
- 2020-11-09
- Volume
- 8
- Issue
- 6
- Pages
- e00682-e00682
- ISSN
- 2052-1707 (ISSN-L)
- OpenAlex
- W3103002655
- Cited by
- 257
- References
- 90
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.